Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK1 | P53355 | 1/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 6/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | MGMT | P16455 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496465 | 1.00 | DAPK1 (0.46) | DAPK1YTHDC1ADORA2AMGMTNT5E | |
| SCHEMBL20555334 | 0.84 | PNP (0.36) | YTHDC1DGAT1 | |
| SCHEMBL20555316 | 0.83 | YTHDC1 (0.38) | YTHDC1DGAT1 | |
| SCHEMBL12537185 | 0.82 | DGAT1 (0.40) | YTHDC1ADORA2ADGAT1 | |
| SCHEMBL3267555 | 0.80 | P2RX7 (0.43) | YTHDC1DGAT1 | |
| SCHEMBL30496451 | 0.80 | P2RX7 (0.43) | YTHDC1DGAT1 | |
| SCHEMBL10577131 | 0.79 | DAPK1 (0.45) | DAPK1YTHDC1ADORA2AMGMTNT5E | |
| SCHEMBL29864160 | 0.79 | DGAT1 (0.40) | DGAT1PIN1 | |
| SCHEMBL10579865 | 0.79 | DAPK1 (0.46) | DAPK1YTHDC1ADORA2AMGMTNT5E | |
| SCHEMBL4112973 | 0.78 | DGAT1 (0.38) | YTHDC1ADORA2ADGAT1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157739-B2 | Hypoxanthine compounds | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-12-03 | — | — | US | disclosed |
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-15 | — | — | US | disclosed |
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3819299-A1 | HYPOXANTHINE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-12 | — | — | EP | disclosed |
| EP-3819299-A1 | HYPOXANTHINE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020054825-A1 | HYPOXANTHINE COMPOUND | キッセイ薬品工業株式会社 | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157739-B2 | Hypoxanthine compounds | HPRT1, APRT, IMPDH1 | DAPK1 4479/4885YTHDC1 651/4885ADORA2A 1186/4885 |
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | HPRT1, DHPS, PAH | DAPK1 4081/4885YTHDC1 611/4885ADORA2A 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.